BioPharmSignal logoBioPharmSignal

Biotech News

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

Emergent BioSolutions (EBS)Emergent BioSolutionsCommercial

WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN ® Nasal Spray for the province’s Take-Home Naloxone Program (BC THN Program).

Related news

EBSEmergent BioSolutions2026-04-29 10:53 EST

Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives

EBSEmergent BioSolutions2026-04-30 11:55 EST

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

View all latest news

Emergent BioSolutions

Emergent BioSolutions is a biodefense and specialty products company focused on public-health preparedness, vaccines, and medical countermeasures. Its business is centered on government and specialty healthcare contracts.

Recent company news

EBSEmergent BioSolutions2026-05-28 20:01 EST

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

EBSEmergent BioSolutions2026-05-20 11:30 EST

Emergent BioSolutions to Participate in Upcoming Investor Conferences

EBSEmergent BioSolutions2026-05-18 12:59 EST

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

EBSEmergent BioSolutions2026-04-30 20:30 EST

Emergent BioSolutions Reports First Quarter 2026 Financial Results

EBSEmergent BioSolutions2026-04-30 11:55 EST

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Stock data

Close
4.82 USD
Market cap
423.61M USD
Exchange
NYSE
Sector
Biopharma
Location
United States